Anticholinergic Medication Burden–Associated Cognitive Impairment in Schizophrenia
2021/05/14 by Yash B. Joshi, Michael L. Thomas, David L. Braff +21 · 25 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Schizophrenia research and treatment #Dementia and Cognitive Impairment Research #Phosphodiesterase function and regulation
paper · doi:10.1176/appi.ajp.2020.20081212
Abstract
OBJECTIVE: Many psychotropic medications used to treat schizophrenia have significant anticholinergic properties, which are linked to cognitive impairment and dementia risk in healthy subjects. Clarifying the impact of cognitive impairment attributable to anticholinergic medication burden may help optimize cognitive outcomes in schizophrenia. The aim of this study was to comprehensively characterize how this burden affects functioning across multiple cognitive domains in schizophrenia outpatients. METHODS: Cross-sectional data were analyzed using inferential statistics and exploratory structural equation modeling to determine the relationship between anticholinergic medication burden and cognition. Patients with a diagnosis of schizophrenia or schizoaffective disorder (N=1,120) were recruited from the community at five U.S. universities as part of the Consortium on the Genetics of Schizophrenia-2. For each participant, prescribed medications were rated and summed according to a modified Anticholinergic Cognitive Burden (ACB) scale. Cognitive functioning was assessed by performance on domains of the Penn Computerized Neurocognitive Battery (PCNB). RESULTS: ACB score was significantly associated with cognitive performance, with higher ACB groups scoring worse than lower ACB groups on all domains tested on the PCNB. Similar effects were seen on other cognitive tests. Effects remained significant after controlling for demographic characteristics and potential proxies of illness severity, including clinical symptoms and chlorpromazine-equivalent antipsychotic dosage. CONCLUSIONS: Anticholinergic medication burden in schizophrenia is substantial, common, conferred by multiple medication classes, and associated with cognitive impairments across all cognitive domains. Anticholinergic medication burden from all medication classes-including psychotropics used in usual care-should be considered in treatment decisions and accounted for in studies of cognitive functioning in schizophrenia.
Cited by
- Two Hypotheses on the High Incidence of Dementia in Psychotic Disorders. [europepmc]
- Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia: A Systematic Literature Review. [europepmc]
- Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art. [europepmc]
- The Basal Forebrain Cholinergic Nuclei and Their Relevance to Schizophrenia and Other Psychotic Disorders. [europepmc]
- European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia. [europepmc]
- Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature. [europepmc]
- Management of cognitive and negative symptoms in schizophrenia. [europepmc]
- Biopsychology of Physical Activity in People with Schizophrenia: An Integrative Perspective on Barriers and Intervention Strategies. [europepmc]
- Gender Difference in Cognitive Function Among Stable Schizophrenia: A Network Perspective. [europepmc]
- Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. [europepmc]
- Dementia among older people with schizophrenia: an update on recent studies. [europepmc]
- Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine. [europepmc]
- Cross-diagnostic determinants of cognitive functioning: the muscarinic cholinergic receptor as a model system. [europepmc]
- Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. [europepmc]
- Clarifying directional dependence among measures of early auditory processing and cognition in schizophrenia: leveraging Gaussian graphical models and Bayesian networks. [europepmc]
- Advancing understanding of the mechanisms of antipsychotic-associated cognitive impairment to minimise harm: a call to action. [europepmc]
- An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders. [europepmc]
- Five-week music therapy improves overall symptoms in schizophrenia by modulating theta and gamma oscillations. [europepmc]
- Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia. [europepmc]
- Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives. [europepmc]
- Treatment of Cognitive Impairment Associated with Schizophrenia Spectrum Disorders: New Evidence, Challenges, and Future Perspectives. [europepmc]
- Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations. [europepmc]
- The potential of muscarinic M 1 and M 4 receptor activators for the treatment of cognitive impairment associated with schizophrenia. [europepmc]
- How antipsychotics work in schizophrenia: a primer on mechanisms. [europepmc]
- A New Era of Muscarinic Acetylcholine Receptor Modulators in Neurological Diseases, Cancer and Drug Abuse. [europepmc]
Related